Financial Highlights of Q3 2025
Embla Medical hf has posted impressive financial results for the third quarter of 2025, marking a significant 11% increase in sales. According to Sveinn Sölvason, President and CEO, sales traffic during this quarter amounted to USD 237 million. This growth was fueled by a pivotal surge mainly in the Prosthetics and Neuro Orthotics sectors.
Growth in Key Segments
The robust upward trend within the EMEA region continues to bolster the company’s revenue figures. Although sales in the Bracing & Supports and Patient Care segments exhibited some stagnation, the company views its recent acquisition of Streifeneder ortho.production as an essential strategic move. This investment allows Embla to enhance its market position within orthopedic solutions and extends its reach into emerging markets.
Segment-Specific Insights
Noteworthy is the 13% organic growth recorded in the Prosthetics & Neuro Orthotics category, contrasting with a flat-line performance observed in the Bracing & Supports segment for this quarter. This dynamic shift illustrates how innovation, particularly through products like Navii and Pro-Flex Terra, continues to play a critical role in revenue growth.
Profitability Metrics and Performance
In terms of profitability, Embla Medical had a commendable EBITDA margin of 22% for Q3 2025 and 21% for the nine months ending the quarter, which is an increase from 20% in the previous year. The solid gross profit margin of 63% was consolidated by operational improvements alongside strong sales performance, particularly from the Prosthetics and Neuro Orthotics segments.
Impact of Strategic Investments
In late August, the company concluded a major investment acquiring a 51% stake in Streifeneder ortho.production, an influential player in the orthopedic mobility solutions sector. With expectations of enhancing their product offerings through this acquisition, Embla Medical aims to broaden its influence across critical markets and continue pushing innovation in healthcare solutions.
Looking Ahead: 2025 Outlook
Embla Medical has reiterated its guidance for organic sales growth in the range of 5%-6% and maintains an EBITDA margin goal between 20%-21%. These forecasts are firmly grounded in the company's strategic initiatives to enhance product offerings and expand into new markets.
Important Financial Metrics
- Net profit for the quarter reached USD 26 million, reflecting a 17% increase compared to the same period last year.
- Free cash flow amounted to USD 38 million, or 16% of sales, demonstrating solid operational execution.
- The net interest-bearing debt to EBITDA ratio was measured at 2.5x, aligning with the targeted leverage range of 2.0-3.0x.
Corporate Commitment
Embla Medical continues to reinforce its commitment to sustainable practices as a signatory of the UN Global Compact and the UN Women's Empowerment Principles. Their climate initiatives, validated by the Science Based Targets initiative, are a testament to the company’s forward-thinking approach in harmonizing environmental stewardship with business growth.
Conference Call and Investor Relations
Embla Medical will be hosting a conference call to provide more insights into these results, scheduled for early next month. Interested participants are encouraged to access the details on the company’s investor relations site.
Frequently Asked Questions
What were Embla Medical's sales for Q3 2025?
Embla Medical reported sales of USD 237 million for Q3 2025.
How has the EBITDA margin changed?
The EBITDA margin was 22% for Q3 2025, which is a positive change compared to the previous year.
What segments showed growth?
The Prosthetics & Neuro Orthotics segment saw 13% organic growth.
What is the company's outlook for 2025?
Embla Medical anticipates organic growth of 5%-6% and an EBITDA margin between 20%-21% for 2025.
Who can I contact for investor relations inquiries?
Klaus Sindahl, Head of Investor Relations, can be contacted at KSindahl@emblamedical.com or by phone at +45 5363 0134.
